Progesterone – promoter or inhibitor of breast cancer

References

• Dietel M. Hormone replacement therapy (HRT), breast cancer and tumor pathology. Maturitas 2010;65:183–9
   PubMed Web of Science ®Google Scholar
• Keeling JW, Ozer E, King G, Walker F. Oestrogen receptor alpha in female fetal, infant, and child mammary tissue. J Pathol 2000;191:449–51
   PubMed Web of Science ®Google Scholar
• Schneider HP, Böcker W. Hormones and progeny of breast tumor cells. Climacteric 2006;9:88–107
   PubMed Web of Science ®Google Scholar
• Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer 2011;2:85–90
   PubMedGoogle Scholar
• Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 2004;9:3–13
   PubMed Web of Science ®Google Scholar
• Clarke RB, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrinol Metab 2004;15:316–23
   PubMed Web of Science ®Google Scholar
• Ferguson JP, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the “resting” human breast. Br J Cancer 1981;44:177–81
   PubMed Web of Science ®Google Scholar
• Conneely OM, Jericevic BM, Lydon JP. Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2003;8:205–14
   PubMed Web of Science ®Google Scholar
• Shaaban AM, O’Neill PA, Davies MP, et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003;27:1502–12
   PubMed Web of Science ®Google Scholar
• Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000;21:40–54
   PubMed Web of Science ®Google Scholar
• Dwivedy I, Devanesan P, Cremonesi P; Rogan E, Cavalieri E. Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinines versus horseradish peroxidase-activated catechol estrogens. Chem Res Toxicol 1992;5:828–33
   Google Scholar
• Mueck AO, Seeger H. Breast cancer: are oestrogen metabolites carcinogenic? Maturitas 2007;57:42–6
   PubMed Web of Science ®Google Scholar
• Obi N, Vrieling A, Heinz J, Chang-Claude J. Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16α-hydroxyestrone ratio predictive for breast cancer? Int J Women's Health 2011;3:37–51
   PubMedGoogle Scholar
• Eden JA. Breast cancer, stem cells and sex hormones. 3, The impact of the menopause and hormone replacement. Maturitas 2011;68:129–36
   PubMed Web of Science ®Google Scholar
• Dontu G, El-Ashry, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004;15:193–7
   PubMed Web of Science ®Google Scholar
• Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 2006;13:617–28
   PubMed Web of Science ®Google Scholar
• Joshi PA, Di Grappa MA, Khokha R. Active allies: hormones, stem cells and the niche in adult mammopoiesis. Trends Endocrinol Metab 2012;23:299–309
   PubMed Web of Science ®Google Scholar
• MacMahon B, Cole P, Lin TM, et al. Age at first birth and breast cancer risk. Bull World Health Organ 1970;43:209–21
   PubMed Web of Science ®Google Scholar
• Russo IH, Russo J. Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia 2011;16:221–33
   PubMed Web of Science ®Google Scholar
• Russo J, Balogh GA, Heulings R, et al. Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev 2006;15:306–42
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison FJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983–8
   PubMed Web of Science ®Google Scholar
• Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: re-analysis of nine prospective studies. J Natl Cancer Inst 2002;94:606–16
   PubMed Web of Science ®Google Scholar
• Thijssen JHH. Local biosynthesis and metabolism of oestrogens in the human breast. Maturitas 2004;49:25–33
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC. Aromatase, 17beta-hydroxysteroid dehydrogenase, and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986;22:515–25
   PubMedGoogle Scholar
• Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003;86:245–53
   PubMed Web of Science ®Google Scholar
• Yaghjyan L, Colditz GA. Estrogens in the breast tissue: a systematic review. Cancer Causes Control 2011;22:529–40
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023–8
   PubMed Web of Science ®Google Scholar
• Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814–19
   PubMed Web of Science ®Google Scholar
• Menard S, Casalini P, Agresti R, Pilotti S, Balsari A. Proliferation of breast carcinoma during menstrual phases. Lancet 1998;352:148–9
   PubMed Web of Science ®Google Scholar
• Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011;13:223–34
   PubMed Web of Science ®Google Scholar
• Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798–808
   PubMed Web of Science ®Google Scholar
• Yaffe M, Hendrix S, Pike M, Santen R, Eden J, Genazzani AR. Is mammographic density, as currently measured, a robust surrogate marker for breast cancer? Gynecol Endocrinol 2005;21(Suppl 1):17–21
   PubMedGoogle Scholar
• Gram IT, Funkhouser E, Tabar L. Reproductive and menstrual factors in relation to mammographic parenchymal patterns among perimenopausal women. Br J Cancer 1995;71:647–50
   PubMed Web of Science ®Google Scholar
• Greendale GA, Palla SL, Ursin G, et al. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Mammographic Density Study. Am J Epidemiol 2005;162:826–34
   PubMed Web of Science ®Google Scholar
• Johansson H, Gandini S, Bonanni B, et al. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat 2008;108:57–67
   PubMed Web of Science ®Google Scholar
• Vachon CM, Sasano H, Ghosh K, et al. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 2011;125:243–52
   PubMed Web of Science ®Google Scholar
• Checka CM, Chun JE, Schnabel FR, Lee J, Toth H. The relationship of mammographic density and age: implications for breast cancer screening. AJR 2012;198:W292–5
   PubMed Web of Science ®Google Scholar
• Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741–51
   PubMed Web of Science ®Google Scholar
• Lahmann PH, Lissner L, Gullberg B, Olsson H, Berglund G. A prospective study of adiposity and postmenopausal breast cancer risk: the Malmö Diet and Cancer Study. Int J Cancer 2003;103:246–52
   PubMed Web of Science ®Google Scholar
• Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomark Prev 2004;13:220–4
   PubMed Web of Science ®Google Scholar
• van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight and breast cancer risk. Am J Epidemiol 2000;152:514–27
   PubMed Web of Science ®Google Scholar
• Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002;42:S31–5
   PubMedGoogle Scholar
• Kerlikowske K, Cook AJ, Buist DSM, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010;28:3830–7
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen–progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262–9
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Slone S, Wasilauskas X, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30–7
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Kuhl H. Is the elevated breast cancer risk observed in the WHI study an artifact? Climacteric 2004;7:319–23
   PubMed Web of Science ®Google Scholar
• McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366–75
   PubMed Web of Science ®Google Scholar
• Boyd NF, Martin L, Chavez S, et al. Breast tissue composition and other risk factors for breast cancer in young women: a cross-sectional study. Lancet Oncol 2009;10:569–80
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Ferguson DJP, Raab GM. Cell turnover in the “resting” human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 1982;46:376–82
   PubMed Web of Science ®Google Scholar
• Navarrete MA, Maier CM, Fakzoni R. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res 2005;7:R306–13
   PubMed Web of Science ®Google Scholar
• Reid SE, Murthy MS, Kaufman M, Scanlon EF. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996;83:1037–46
   PubMed Web of Science ®Google Scholar
• Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003;5:R129–35
   PubMed Web of Science ®Google Scholar
• Guo YP, Martin L, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomark Prev 2001;10:243–8
   PubMed Web of Science ®Google Scholar
• Li T, Sun L, Miller N, et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:343–9
   PubMed Web of Science ®Google Scholar
• Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382–93
   PubMed Web of Science ®Google Scholar
• Graham SJ, Stanchev PL, Lloyd-Smith JOA, Bronskill MJ, Plewes DB. Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR Imaging at 1.5 T. JMRI 1995;5:695–701
   Web of Science ®Google Scholar
• Stoeckelhuber M, Stumpf P, Hoefter EA, Welsch U. Proteoglycan–collagen associations in the non-lactating human breast connective tissue during the menstrual cycle. Histochem Cell Biol 2002;118:221–30
   PubMed Web of Science ®Google Scholar
• Warren R, Lakhani SR. Can the stroma provide the clue to the cellular basis for mammographic density? Breast Cancer Res 2003;5:225–7
   PubMed Web of Science ®Google Scholar
• Haslam SZ, Woodward TL. Tumour–stroma interactions – reciprocal regulation of extracellular matrix proteins and ovarian steroid activity in the mammary gland. Breast Cancer Res 2001;3:365–72
   PubMed Web of Science ®Google Scholar
• Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signalling molecules. Cell Tissue Res 2010;339:237–46
   PubMed Web of Science ®Google Scholar
• Skandalis SS, Labropoulou V, Ravazoula P, et al. Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer 2011;11:314–26
   PubMedGoogle Scholar
• Kass L, Erler JT, Dembo M, Weaver VM. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol 2007;39:1987–94
   PubMed Web of Science ®Google Scholar
• Yoneda A, Lendorf ME, Couchman JR, Multhaupt HAB. Breast and ovarian cancers: a survey and possible roles for the cell surface heparin sulphate proteoglycans. J Histochem Cytochem 2011;60:9–21
   Web of Science ®Google Scholar
• Esko JD, Kimata K, Lindahl U. Proteoglycans and sulfated glycosaminoglycans. In Varki A, Cummings RD, Esko JD, et al., eds. Essentials of Glycobiology, 2nd edn. New York: Cold Spring Harbor Laboratory Press, 2009: Chapter 16
   Google Scholar
• Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 2010;277:3904–23
   PubMed Web of Science ®Google Scholar
• Bernert B, Porsch H, Heldin P. Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J Biol Chem 2011;286:42349–59
   PubMed Web of Science ®Google Scholar
• Viola M, Vigetti D, Genasetti A, et al. Molecular control of the hyaluronan biosynthesis. Connect Tiss Res 2008;49:111–14
   PubMed Web of Science ®Google Scholar
• Corte MD, Gonzalez LO, Lamelas ML, et al. Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer. Breast Cancer Res Treat 2006;97:329–37
   PubMed Web of Science ®Google Scholar
• Sunil N, Srinivasan N, Aruldhas MM, Govindarajulu P. Impact of oestradiol and progesterone on the glycosaminoglycans and their depolymerising enzymes of the rat mammary gland. Acta Physiol Scand 2000;168:385–92
   PubMedGoogle Scholar
• Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002;14:617–23
   PubMed Web of Science ®Google Scholar
• Iozzo RV, Schaefer L. Proteoglycans in health and disease: novel regulatory signalling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 2010;277:3864–75
   PubMed Web of Science ®Google Scholar
• Goldoni S, Seidler DG, Heath J, et al. An antimetastatic role for decorin in breast cancer. Am J Pathol 2008;173:844–55
   PubMed Web of Science ®Google Scholar
• Goldoni S, Iozzo RV. Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 2008;123:2473–9
   Google Scholar
• Troup S, Njue C, Kliewer EV, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 2003;9:207–14
   PubMed Web of Science ®Google Scholar
• Löfgren L, Sahlin L, Jiang S, et al. Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res 2007;27:3045–50
   PubMed Web of Science ®Google Scholar
• Kousidou OC, Berdiaki A, Kletsas D, et al. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2008; 2:223–32
   PubMed Web of Science ®Google Scholar
• Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717–22
   PubMed Web of Science ®Google Scholar
• Wiebe JP. Progesterone metabolites in breast cancer. Endocr Related Cancer 2006;13:717–38
   PubMed Web of Science ®Google Scholar
• Wiebe JP, Beausoleil M, Zhang G, Cialacu V. Opposing actions of the progesterone metabolites, 5α-dihydroprogesterone (5αP) and 3α-dihydroprogesterone (3αHP) on mitosis apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines. J Steroid Biochem Mol Biol 2010;118:125–32
   PubMed Web of Science ®Google Scholar
• Wiebe JP, Lewis MJ, Cialacu V, Pawlak KJ, Zhang G. The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J Steroid Biochem Mol Biol 2005;93:201–8
   PubMed Web of Science ®Google Scholar
• Murkes D, Conner P, Leifland K, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188–91
   PubMed Web of Science ®Google Scholar
• Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963–9
   PubMed Web of Science ®Google Scholar
• Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125–34
   PubMed Web of Science ®Google Scholar
• Hümpel M, Düsterberg B, Beier S, Schuppler J, Gunzel P, Elger W. The role of pharmacokinetics in preclinical safety studies of synthetic sex steroids. In Gregoire AT, Blye RP, eds. Contraceptive Steroids – Pharmacology and Safety. New York: Plenum Press, 1986:47–65
   Google Scholar
• Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 2012;15:18–25
   PubMed Web of Science ®Google Scholar
• Clavel-Chapelon F, the E3N Group. E3N, a French cohort study on cancer risk factors. Eur J Cancer Prev 1997;6:473–8
   PubMed Web of Science ®Google Scholar
• Bergström A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421–30
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen–progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;31:5138–43
   Google Scholar
• Levine H, Watson N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril 2000;73:516–21
   PubMed Web of Science ®Google Scholar
• Nahoul K, Dehennin L, Scholler R. Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone. J Steroid Biochem 1987;26:241–9
   PubMedGoogle Scholar
• Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993;16:185–202
   PubMed Web of Science ®Google Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010;172:1394–403
   PubMed Web of Science ®Google Scholar
• Ahn J, Schatzkin A, Lacey JV, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007;167:2091–102
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Bahl M, et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 2009;114:517–25
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-1, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48–60
   PubMed Web of Science ®Google Scholar
• Gupta K, Krishnaswamy G, Karnad A, Peiris AN. Insulin: a novel factor in carcinogenesis. Am J Med Sci 2002;323:140–5
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 2004;15:267–75
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEPI Trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–5.
   PubMed Web of Science ®Google Scholar
• Pelissier C, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Jondet M. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas 2001;40:85–94
   PubMed Web of Science ®Google Scholar